Trials / Completed
CompletedNCT00399477
A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease
Open-label, Multicenter, Effectiveness and Safety Study of Once Daily AZILECT® as Mono- or Adjunct Therapy in Patients With Idiopathic Parkinson's Disease (PD)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- Teva Neuroscience, Inc. · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
Patients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at their first visit based on the drugs they are taking for their PD: * Group 1 Patients using Azilect and no other therapy. * Group 2 Azilect in combination with other medications like Levodopa, Mirapex, or Requip.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rasagiline mesylate | Azilect® |
| DRUG | Rasagiline mesylate plus Mirapex | Mirapex, Azilect® |
| DRUG | Rasagiline mesylate with Levodopa | Azilect®, Levodopa |
| DRUG | Rasagiline mesylate with Requip | Azilect®, Requip |
Timeline
- Start date
- 2006-10-01
- Primary completion
- 2007-07-01
- Completion
- 2007-07-01
- First posted
- 2006-11-14
- Last updated
- 2011-04-12
Source: ClinicalTrials.gov record NCT00399477. Inclusion in this directory is not an endorsement.